[ad_1]
Wednesday August 11, 2021
Zacks Research Daily features the best research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), AbbVie Inc. (ABBV) and Exxon Mobil Corporation (XOM). These research reports were handpicked from the roughly 70 reports released by our team of analysts today.
You can see all today’s research reports here >>>
Actions of Ali Baba have suffered in recent times, as have other Chinese tech stocks, in response to regulatory crackdown by Chinese authorities. While these short-term headwinds are all too real, the company remains well positioned for long-term investors.
Strengthening its cloud business continues to drive performance through a growing customer base. Growing competition from domestic and foreign e-commerce companies poses a serious risk, however. Regulatory concerns and the higher costs associated with new initiatives remain major obstacles.
(You can read the full research report on Alibaba here >>>)
AbbVie stocks have gained + 12.2% in the past six months against Zacks Large-Cap’s + 16.1% pharmaceutical gain, however, its second quarter profits were in line with estimates while sales were beating the same. Zacks analyst believes AbbVie’s flagship product Humira continues to generate revenue
It has an impressive late stage pipeline with several early / middle stage candidates who have immense potential. Skyrizi and Rinvoq, two of its new immunological drugs, have exceeded expectations. The erosion of sales due to direct competition from Humira’s biosimilars in international markets is, however, a strong headwind. Another concern is the uncertainty surrounding the FDA’s decision on Rinvoq’s label extension filings due to controversies surrounding JAK inhibitor drugs.
(You can read the full research report on AbbVie here >>>)
Actions of Exxon Mobil gained + 44.8% over the year-to-date period versus Zacks’ integrated international oil industry gain of + 30.1%. The Zacks analyst believes that the major discoveries in the Stabroek block have improved the outlook for ExxonMobil’s upstream business.
The company recently reported strong second quarter results, driven by improved realized oil and gas prices as well as higher chemical margins. However, its downstream activity suffered from planned maintenance and an unfavorable exchange rate. Lower margins due to weak refining activities continue to hurt the downstream activities of the integrated energy player in the United States.
(You can read the full research report on Exxon Mobil here >>>)
Other noteworthy reports we feature today include Sony Group Corporation (SONY), American Tower Corporation (AMT) and Caterpillar Inc. (CAT).
Sheraz Mian
Research Director
Note: Sheraz Mian heads Zacks’ equity research department and is a renowned expert on aggregate earnings. He is frequently cited in print and electronic media and publishes the weekly Income trends and Income overview reports. If you would like to receive an email notification every time Sheraz publishes a new article, please click here >>>
[ad_2]
